Drug Profile
CS 891
Alternative Names: CS 891BLatest Information Update: 12 Jun 2003
Price :
$50
*
At a glance
- Originator Sankyo
- Class
- Mechanism of Action Cholestenone 5-alpha reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alopecia; Benign prostatic hyperplasia
Most Recent Events
- 12 Jun 2003 Discontinued - Phase-II for Benign prostatic hyperplasia in Europe (PO)
- 12 Jun 2003 Discontinued - Phase-II for Benign prostatic hyperplasia in USA (PO)
- 28 Jun 2001 Phase-II clinical trials for Alopecia in USA (PO)